 |
| Days sales outstanding, days inventory outstanding, days payables outstanding, and days working capital in 67 industry sectors. |
|
|
CFO Staff,
CFO Magazine
|
|
| BIOTECHNOLOGY |
| COMPANY |
DSO |
DIO |
DPO |
DWC |
| 2003 |
Change '03 - '02 |
Change '02 - '01 |
2003 |
Change '03 - '02 |
Change '02 - '01 |
2003 |
Change '03 - '02 |
Change '02 - '01 |
2003 |
Change '03 - '02 |
Change '02 - '01 |
| QUINTILES TRANSNATIONAL |
43 |
-9% |
+4% |
0 |
N/M |
N/M |
11 |
+4% |
-14% |
32 |
-12% |
+11% |
| QUEST DIAGNOSTICS |
47 |
+1% |
-9% |
6 |
+3% |
+8% |
9 |
-8% |
-1% |
43 |
+4% |
-9% |
| BIOGEN |
56 |
+3% |
-12% |
27 |
-11% |
+67% |
34 |
+65% |
+16% |
49 |
-24% |
+3% |
| LABORATORY CORP OF AMERICA |
54 |
-6% |
-6% |
6 |
-10% |
+2% |
9 |
-22% |
+16% |
50 |
-3% |
-9% |
| AMGEN |
44 |
-11% |
+10% |
31 |
-14% |
+11% |
14 |
-15% |
+35% |
61 |
-12% |
+6% |
| COVANCE |
75 |
+14% |
-8% |
15 |
-11% |
+9% |
8 |
-24% |
+11% |
83 |
+14% |
-7% |
| CHIRON |
79 |
-1% |
+11% |
41 |
-1% |
+17% |
21 |
+25% |
-7% |
99 |
-5% |
+17% |
| GENENTECH |
63 |
+9% |
-3% |
52 |
-5% |
-12% |
7 |
-8% |
+23% |
109 |
+3% |
-9% |
| GENZYME |
85 |
+7% |
+2% |
57 |
-13% |
+28% |
14 |
+15% |
-15% |
127 |
-4% |
+16% |
| BIO RAD LABORATORIES |
85 |
-2% |
-0% |
69 |
+2% |
+9% |
20 |
-36% |
+6% |
135 |
+9% |
+3% |
| MONSANTO |
166 |
+21% |
-11% |
89 |
-10% |
+10% |
21 |
-2% |
-30% |
234 |
+9% |
+0% |
| Sector Average |
72 |
+3% |
-11% |
37 |
-10% |
+1% |
14 |
-9% |
-9% |
95 |
-1% |
-7% |
All data based on public financials and adjusted as needed for comparability.
DSO: Days Sales Outstanding
DIO: Days Inventory Outstanding
DPO: Days Payables Outstanding
DWC: Days Working Capital
* Adjusted for effects of securitization
N/M: Not meaningful
Source: REL Consultancy Group
|
Video
